Following US antitrust clearance, Daiichi Sankyo has completed its acquisition of Plexxikon, successfully sealing a $935 million transaction that will see the formerly private US firm continuing to operate as an independent R&D unit of the Japanese major.
Following US antitrust clearance, Daiichi Sankyo has completed its acquisition of Plexxikon, successfully sealing a $935 million transaction that will see the formerly private US firm continuing to operate as an independent R&D unit of the Japanese major.
The main driving force for the deal, first announced around a month ago, is Daiichi Sankyo's desire to bolster its presence in oncology, where a number of leading Japanese pharma companies have made large acquisitions over the past few years
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
